Cipla Q4 Results: Date, Dividend, Earnings Conference Call Details And More

Cipla Ltd. is scheduled to report its earnings for the fourth quarter and fiscal ended March 31, 2025, this week. The leading pharmaceutical company earlier announced the date of the results in a regulatory filing to the stock exchanges.

Here are all the key details you need to know about the Q4 and FY25 results of Cipla Ltd.

Cipla Ltd. has announced that a meeting of its Board of Directors will be held on Tuesday, May 13, 2025, to consider and approve important financial matters. The Board will review and approve the standalone and consolidated audited financial results of the company for the quarter and year ended March 2025. Additionally, the Board will discuss and recommend the final dividend for the financial year, if any.

Cipla Ltd. has informed the stock exchanges that, in compliance with SEBI rules, the trading window for dealing in the company's securities has been closed from Tuesday, April 1, 2025. It will remain shut until Thursday, May 15, 2025, both days inclusive. The trading restrictions will be applicable to designated persons and their immediate relatives, as per the SEBI guidelines, to prevent insider trading.

Cipla Ltd. has announced that following the release of its financial results for the fourth quarter and fiscal ended March 31, 2025, the company’s leadership team will host an earnings conference call on May 13 at 4 p.m. During the call, the management will discuss the company’s financial performance and address questions from investors and analysts.

The conference call timings in other regions are as follows:

• 1830 hrs SST/HKT

• 1130 hrs BST

• , 0630 hrs hrs US ET

Here are the dial-in numbers for participants to access the call:

Primary Access (India):

1. +91 22 6280 1562

2. +91 22 7115 8387

Toll-Free Numbers:

1. USA: 1-866-746-2133

2. UK: 0808-101-1573

3. Hong Kong: 800-964-448

4. Singapore: 800-101-2045

Cipla Ltd reported a 49.7% year-on-year increase in consolidated net profit for the quarter ended December 2024, reporting Rs 1,571 crore compared to Rs 1,049 crore in the same period of FY24. The company’s consolidated revenue from operations rose to Rs 7,072.97 crore in the December quarter, up from Rs 6,603.81 crore in the year-ago period.

The company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) climbed 15.7% year-on-year to Rs 1,989 crore, compared to Rs 1,720 crore a year ago. The EBITDA margin also improved, expanding to 28.1% from 26.3% in the corresponding period a year ago.

In the past five trading sessions, Cipla’s stock has declined by 2.87%. It has fallen nearly 1% in the last month. The pharma stock has fallen 3.75% over the past six months and 4% year-to-date. However, in the last year, the stock has gained 3.77%.

Shares of Cipla Ltd. hit a 52-week high of Rs 1,702.05 apiece on Oct. 9, 2024, and a 52-week low of Rs 1,317.25 on May 10, 2024.

Cipla shares were trading 0.8% down at Rs 1,468.00 apiece on the NSE on Monday, as of 9:40 a.m. This compares to a 2.54% rise in benchmark Nifty 50.